Mpox Vaccinations Uptake Plateaued at 25%

In May 2022, when the mpox outbreak was first reported in Europe, most government health agencies started giving out Bavarian Nordic's JYNNEOS® (MVA-BN®, IMVAMUNE®) vaccine for free to eligible individuals.

As per a recent alert by the U.S. CDC COCA, only 25% of the two million eligible people have completed the JYNNEOS two-dose vaccination series in the U.S.

The CDC stated on February 12, 2024, that although the number of mpox outbreaks in the U.S. has decreased significantly since the summer of 2022, small clusters of the disease continue to occur, and severe manifestations of mpox, including deaths, are still being reported in 2024.

Furthermore, the CDC strongly urges clinicians, health departments, and community-based organizations to continue recommending the two-dose JYNNEOS vaccine to eligible individuals.

And the CDC is encouraging those who have only received one dose to get the second dose to obtain the best possible protection.

Moreover, the U.S. FDA recently approved JYNNEOS to prevent mpox infection, regardless of the mpox virus Clade.

This vaccine is generally available in major cities at health clinics and pharmacies. If you need more information about this update or wish to provide feedback, please get in touch with the CDC at [email protected].